Atorvastatin treatment inhibits proliferation, Th1 and Th17 differentiation of myelin-reactive T cells but does not expand CD4
regulatory T cells. Splenocytes were isolated from signal transducer and activator of transcription 6 (STAT6)-deficient or wild-type (WT) C57BL/6 mice dosed daily with atorvastatin (AT; 10 mg/kg/day) or vehicle (phosphate-buffered saline (PBS)) for 12 days starting 2 days prior to immunization with myelin oligodendrocyte glycoprotein peptide 35 to 55 (MOG 35–55). (a) Cytokine secretion in response to MOG 35–55 was evaluated by enzyme-linked immunosorbent assay. (b) The frequency of CD4+CD25+FoxP3+ regulatory T cells (Tregs) was evaluated by fluorescence-activated cell sorting. As positive control, mice were injected subcutaneously with 150 μg glatiramer acetate (GA) in PBS per day. Shown is the percentage of CD4+CD25+ Tregs within all CD4+ T cells. Five mice/group were used. Shown is one representative finding out of two independent experiments performed. cpm, counts per minute; FITC, fluorescein isothiocyanate; IFN, interferon; IL, interleukin; PE, phycoerythrin; TNF, tumor necrosis factor.